（一）出席董事会会议和列席股东大会情况 2024 年度，公司共召开董事会 6 次，本人出席会议 6 次，均按时出席，无 缺席或连续两次未亲自出席会议的情况。作为独立董事，本人在召开董事会前会 主动获取作出决策所需要的相关资料，并全面了解公司运营情况，以便为董事会 的重要决策做好前期的准备工作；会上积极参与讨论并提出合理化建议，会后继 续关注议案实施情况，充分发挥了独立董事的积极作用，本人认为 2024 年度任 1 2024 年度独立董事述职报告（戴雪光） 2024 年度，本人作为上海凯利泰医疗科技股份有限公司（以下简称"公司"） 的独立董事，在职期间严格按照《中华人民共和国公司法》、《上市公司独立董 事管理办法》、《深圳证券交易所创业板股票上市规则》《上市公司自律监管指 引第 2 号——创业板上市公司规范运作》、《上市公司独立董事管理办法》及《公 司章程》、《独立董事制度》等规定，认真履行职责，充分发挥独立董事的作用， 恪尽职守，勤勉尽责，维护公司利益，维护全体股东尤其是中小股东的利益，履 行了独立董事的职责，谨慎、认真、勤勉地行使法律所赋予的权利，积极出席相 关会议，对各项议案进行认真审议，充分发挥了独立董 ...

2024 年度独立董事述职报告（鲁旭波） 2024 年度，本人鲁旭波，作为上海凯利泰医疗科技股份有限公司（以下简 称"公司"）的独立董事，严格按照《中华人民共和国公司法》、《深圳证券交易 所创业板股票上市规则》和《上市公司独立董事管理办法》等法律法规以及《公 司章程》的规定，本着客观、公正、独立的原则，勤勉尽责，积极发挥独立董事 作用，维护公司整体利益和全体股东尤其是中小股东的合法权益。现将本人 2024 年度履职情况汇报如下： 一、独立董事的基本情况介绍 报告期内，本人任职符合《上市公司独立董事管理办法》第六条规定的独立 性要求，不存在影响独立性的情况。本人履历如下： 鲁旭波先生，1980 年 3 月出生，中国国籍，无境外居留权，本科学历。2005 年 12 月至 2016 年 6 月任职于浙江康盛股份有限公司，历任董秘助理、证券事务 代表、投资部经理、董事会秘书、董事职务。现任杭州安益资产管理有限公司副 总经理、风控合规负责人。2014 年 8 月 20 日至 2020 年 8 月 19 日担任公司独立 董事。2022 年 6 月至 2025 年 3 月，任公司独立董事。 二、独立董事年度履职情况 （一） ...

上海凯利泰医疗科技股份有限公司 董事会 根据《上市公司独立董事管理办法》《深圳证券交易所创业板股票上市规则》 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 《独立董事工作制度》等相关规定和要求，上海凯利泰医疗科技股份有限公司（以 下简称"公司"）董事会，就公司 2024 年度在任独立董事戴雪光先生、鲁旭波先 生、郑卫茂先生的独立性情况进行评估并出具如下专项意见： 经核查，根据公司 2024 年度在任独立董事戴雪光先生、鲁旭波先生、郑卫 茂先生自查及其在公司的履职情况，董事会认为前述人员均能够胜任独立董事的 职责要求，未在公司担任除独立董事及专门委员会以外的任何职务，也未在公司 主要股东公司担任任何职务，与公司以及主要股东之间不存在利害关系或其他可 能妨碍其进行独立客观判断的关系，不存在影响独立董事独立性的情况，符合《上 市公司独立董事管理办法》等法律法规及《公司章程》中关于独立董事的任职资 格及独立性的相关要求。 上海凯利泰医疗科技股份有限公司董事会 关于对独立董事独立性评估的专项意见 2025 年 4 月 30 日 ...

Financial Performance - The net profit attributable to shareholders for 2024 was -105.57 million RMB, a decrease of 193.80% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -65.31 million RMB, a decline of 205.93% compared to the previous year[5]. - The company's operating revenue for 2024 was ¥984,518,762.54, representing a 2.96% increase compared to ¥956,259,537.45 in 2023[20]. - The cash flow from operating activities decreased by 42.48% to ¥157,752,381.96 in 2024, down from ¥274,260,691.58 in 2023[20]. - The company reported a basic and diluted earnings per share of -¥0.1472 for 2024, compared to ¥0.1570 in 2023, marking a decline of 193.76%[20]. - The company's weighted average return on equity was -3.77% in 2024, down from 4.02% in 2023[20]. - The company’s net profit after deducting non-recurring gains and losses was -¥65,305,422.66 in 2024, a decrease of 205.93% from ¥61,648,763.58 in 2023[20]. - The company reported a net cash flow from operating activities of ¥157,752,381.96 in 2024, a decrease of 42.48% compared to ¥274,260,691.58 in 2023[85]. Impairment and Losses - The company recognized inventory impairment losses of 16.91 million RMB due to changes in market demand and product updates[5]. - The company recorded a long-term equity investment impairment provision of 121.57 million RMB and a fair value change loss of 87.14 million RMB, leading to a total profit reduction of 225.62 million RMB[6]. - The company recognized an inventory impairment provision of RMB 16.85 million due to market demand changes and product updates, including RMB 12.16 million for long-term equity investments[61]. - The company’s non-recurring losses impacted net profit attributable to shareholders by RMB -40.26 million, compared to a gain of RMB 50.89 million in the previous year[61]. - Asset impairment losses totaled 138.48 million, which is 125.47% of total profit, due to inventory write-downs and long-term equity investment losses[89]. Market and Industry Trends - The orthopedic medical device industry in China is experiencing rapid growth, with a significant increase in domestic companies due to the entry of foreign firms and improved technology and management practices[33]. - The average price reduction for orthopedic trauma medical consumables in a centralized procurement led by 12 provinces reached 88.65%, with specific products like ordinary bone plates seeing a price drop from approximately ¥4683 to ¥606, a decrease of 87.05%[34][35]. - The implementation of centralized procurement policies is expected to reduce patient financial burdens and significantly impact the medical device industry's development, leading to the elimination of smaller, less innovative companies[38]. - The orthopedic industry is projected to concentrate around leading domestic companies, enhancing their competitive advantage in the market[39]. - The medical device industry is facing challenges due to policies aimed at controlling medical insurance costs, which may limit the growth of medical device expenses in healthcare institutions[120]. Product Development and Innovation - The company plans to focus on product innovation and explore new materials and technologies to adapt to the changing market landscape and maintain profitability[40]. - The company has been actively developing and researching orthopedic minimally invasive medical devices, covering multiple product lines including spinal and trauma products[32]. - The company is working on multiple new products, including a new expandable interbody fusion device aimed at enhancing spinal product offerings and obtaining FDA registration[83]. - The company plans to expand its trauma plate product line with new models of anatomical metal locking plates, enhancing its product series[83]. - The company is also updating existing surgical instruments to meet market demands, which will improve the usability and competitiveness of its products[83]. Acquisitions and Strategic Partnerships - The company completed the acquisition of 100% equity of Elliquence, LLC for 77,152,000 USD (approximately 495 million CNY) to support its internationalization strategy[95]. - The joint venture with TECRES S.P.A has led to the introduction of advanced bone cement products, enhancing the company's product line in orthopedic materials and establishing a strong foundation for future developments[42]. - Following the acquisition of Aideer, the company has optimized and integrated its orthopedic product lines and sales channels, enhancing its core competitiveness in the orthopedic market[43]. - The company is actively enhancing its distribution channels in the medical device sector, aiming to increase market share and influence through strategic partnerships and a diversified delivery service platform[46]. Financial Management and Governance - The company has established a performance evaluation and incentive system linking management compensation to business performance, ensuring transparency in the hiring of senior management[164]. - The company has strengthened its internal governance structure in compliance with relevant laws and regulations, enhancing operational transparency and accountability[157]. - The company has established and strictly implemented information disclosure management systems to ensure transparency and fairness in information dissemination[165]. - The company maintains complete independence in operations, assets, personnel, finance, and organization, ensuring no conflicts with shareholders[171]. Risks and Challenges - The company faces risks from the expanding volume-based procurement policies, which may lead to significant price reductions and impact sales volume and profitability[138]. - The company anticipates increased market competition in the orthopedic sector, necessitating timely product launches with higher technical content to maintain profit margins[140]. - The company has recognized the potential impact of increased tariffs and trade restrictions on raw material costs and international market demand, which could adversely affect its operating performance[153]. - The company faces inventory devaluation risks due to the transition from a distributor stocking model to a production-based inventory strategy, necessitating improved inventory management to avoid excess stock[150].

Financial Performance - The company's revenue for Q1 2025 was CNY 264.81 million, an increase of 7.56% compared to CNY 246.21 million in the same period last year[7]. - Net profit attributable to shareholders was CNY 21.76 million, representing a 100.03% increase from CNY 10.88 million year-on-year[7]. - The net profit after deducting non-recurring gains and losses was CNY 20.10 million, up 141.84% from CNY 8.31 million in the previous year[7]. - The company’s operating profit and total profit for Q1 2025 were CNY 30.07 million and CNY 30.11 million, respectively, reflecting growth of 53.30% and 53.70% year-on-year[11]. - Total operating revenue for the current period reached ¥264,814,699.46, an increase of 7.0% compared to ¥246,205,033.77 in the previous period[36]. - Net profit for the current period was ¥25,914,508.10, representing a significant increase of 56.5% from ¥16,554,844.75 in the previous period[36]. - The total comprehensive income for the period was CNY 24,741,946.44, compared to CNY 17,866,526.38 in the previous period, representing an increase of approximately 38.5%[38]. Cash Flow - The net cash flow from operating activities was CNY 8.51 million, a significant improvement of 143.65% compared to a negative cash flow of CNY 19.50 million in the same period last year[7]. - The net cash flow from investment activities improved by CNY 16.86 million, reaching -CNY 7.53 million compared to -CNY 24.39 million in the same period last year[26]. - The net cash flow from financing activities was -22.2481 million yuan, a decrease of 31.5657 million yuan compared to the same period last year, primarily due to a reduction in net bank borrowings by 39.8399 million yuan[27]. - The cash inflow from investment activities was CNY 316,947,727.48, compared to CNY 242,065,569.77 in the previous period, marking an increase of about 31%[41]. - The total cash outflow from investment activities was CNY 392,223,062.87, down from CNY 485,919,004.65 in the previous period, indicating a reduction of approximately 19.3%[41]. - The company reported a net increase in cash and cash equivalents of CNY -89,086,230.35 for the period, compared to a net decrease of CNY -253,847,513.70 in the previous period[41]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 3.34 billion, a slight decrease of 0.41% from CNY 3.35 billion at the end of the previous year[7]. - Current liabilities decreased to ¥395,549,959.22 from ¥441,227,382.43, a reduction of 10.4%[34]. - Long-term borrowings increased to ¥10,114,434.77 from ¥9,507,331.35, reflecting a rise of 6.4%[34]. - The company's total equity rose to ¥2,851,868,469.47 from ¥2,818,873,837.76, an increase of 1.2%[34]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 42,248, with no preferred shareholders having restored voting rights[29]. - The top 10 shareholders held a total of 6.99% (50,100,000 shares) by Yongjin Investment Holdings, and 5.03% (36,050,241 shares) by Shanghai Xincheng Yitou[29]. - There were no significant changes in the top 10 shareholders' participation in margin trading or securities lending activities[30]. - The company has not reported any changes in the number of preferred shareholders or any significant changes in restricted shares[31]. Investment Activities - The company reported a significant increase in investment activity cash inflows, totaling CNY 31.69 million, a 30.93% increase from CNY 24.21 million in the previous year[25]. - The company received CNY 7,534,725.66 from minority shareholders as part of investment inflow[41]. - The company’s subsidiary, Jieno Medical, received minority shareholder capital contributions of 7.5347 million yuan during the reporting period[27]. - The company paid minority shareholder profits of 1.0599 million yuan through its subsidiary Shenyang Kailitai during the reporting period[27]. Other Financial Metrics - Basic and diluted earnings per share increased to CNY 0.0303, up 99.34% from CNY 0.0152 year-on-year[7]. - Research and development expenses were ¥12,348,782.57, down from ¥14,979,793.67, a decrease of 17.5%[37]. - The company reported an investment income of ¥634,460.72, a recovery from a loss of ¥2,447,816.57 in the previous period[37]. - The company's cash and cash equivalents were not explicitly detailed, but the overall liquidity position appears stable given the reduction in current liabilities[34]. - Cash and cash equivalents at the end of the period decreased to CNY 232,028,770.15 from CNY 361,137,590.27, a decline of approximately 35.7%[41]. - The trading financial assets increased to 876,860,830.95 yuan from 841,430,441.46 yuan at the beginning of the period[32]. Audit and Reporting - The company did not undergo an audit for the first quarter report[42]. - The company has not disclosed any new product developments or market expansion strategies in the provided content[31].

Core Viewpoint - The internal conflicts within Kailitai (300326.SZ) continue, with significant disagreements over the election of the new chairman, management changes, and the contentious share repurchase issue, leading to potential risks for the company [1][2][14]. Group 1: Internal Conflicts - The board of directors' election revealed deep divisions between the second-largest shareholder and the first and third shareholders, affecting key decisions such as the chairman's election and management appointments [1][3]. - The new chairman, Cai Zhongxi, was elected with 4 votes against 3 for the candidate Wang Chong, representing the first and third shareholders [1][5]. - Management changes included the appointment of Xia Tian as the general manager and Guo Haibo as the board secretary, amidst disagreements over these appointments [1][7]. Group 2: Share Repurchase Disputes - The ongoing dispute regarding the share repurchase from Ligetai has resurfaced, with the board previously voting to issue a repurchase notice, but the decision faced opposition from key stakeholders [8][10]. - The board's recent meeting did not pass the proposal to send a repurchase notice, with votes split and some members calling for more information before making a decision [9][11]. - The repurchase agreement was triggered due to Ligetai's failure to complete an IPO by December 31, 2024, leading to legal actions from the second-largest shareholder [8][12]. Group 3: Internal Control Issues - Kailitai is facing internal control problems, with auditors unable to obtain sufficient evidence regarding the valuation of equity investments and related party transactions, leading to a "non-standard" audit opinion for the 2024 financial report [2][14]. - The company announced a delay in the disclosure of its 2024 annual report due to significant disagreements with auditors, which may result in further regulatory scrutiny [14][15]. Group 4: Shareholder Actions - The second-largest shareholder, represented by Yuan Zheng and Wang Zhengmin, has been increasing their stake in Kailitai, now holding approximately 6.38% of the shares, which is close to the first shareholder's 6.99% [15][16]. - The ongoing increase in shareholding indicates a potential power struggle for control and influence over Kailitai's strategic direction [16].

本公司及监事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、股东提议召开临时股东大会的基本情况 证券代码：300326 证券简称：凯利泰 公告编号：2025-019 上海凯利泰医疗科技股份有限公司 监事会关于不同意召开2025年临时股东大会并向股东回函 的公告 公司于近日召开了第五届监事会第十九次会议，审议《关于股东提请召开临 时股东大会的议案》，该议案以 0 票同意、3 票反对、0 票弃权、0 票回避的表决 结果，未获公司监事会审议通过。 （二）公司监事会不同意股东召开临时股东大会的理由 监事周志强反对理由如下：张斌先生并不存在不符合任职资格的情况，股东 提出罢免张斌担任独立董事无事实及法律依据；股东贸然提出罢免董事将导致公 司治理失序，给公司造成负面影响，并将最终损害中小投资者的利益。 上海凯利泰医疗科技股份有限公司（以下简称"公司"）于近日收到公司合计 持股 10%股东涌金投资控股有限公司（以下简称"涌金投资"）、上海凯诚君泰投 资有限公司（以下简称"凯诚君泰"）送达的《关于召开临时股东大会的请求》。 涌金投资、凯诚君泰作为合计持有公司 10%以上股份的股东，已 ...

证券代码：300326 证券简称：凯利泰 公告编号：2025-018 上海凯利泰医疗科技股份有限公司 第五届监事会第十九次决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 上海凯利泰医疗科技股份有限公司（以下简称"公司"）以邮件方式向公司 各监事发出关于召开第五届监事会第十九次会议的通知，并于近日以通讯方式召 开。本次监事会会议应出席的监事 3 名，实际出席会议的监事 3 名，均以通讯表 决方式出席会议。会议由周志强先生主持，公司董事会秘书列席本次会议。本次 会议的召集、召开符合《中华人民共和国公司法》和《上海凯利泰医疗科技股份 有限公司章程》的规定。 二、监事会会议审议情况 审议未通过《关于股东提请召开临时股东大会的议案》 公司股东涌金投资控股有限公司（以下简称"涌金投资"）及上海凯诚君泰 投资有限公司（以下简称"凯诚君泰"，与涌金投资合称"提议人"）向公司监事 会发出《关于召开临时股东大会的请求》函件（以下简称"请求函"），要求召开 临时股东大会审议关于《罢免张斌担任公司第六届董事会独立董事》的议案，议 案具体内容如下："张 ...

证券代码：300326 证券简称：凯利泰 公告编号：2025-017 上海凯利泰医疗科技股份有限公司 董事会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 上海凯利泰医疗科技股份有限公司（以下简称"凯利泰"或"公司"）于近 日在公司会议室以现场结合通讯方式召开了第六届董事会第一次、第二次会议。 会议应出席的董事 7 名，实际出席会议的董事 7 名，其中蔡仲曦、金诗强、王冲、 惠一微、狄朝平、张斌、朱丁敏以通讯表决方式出席会议。公司部分监事和高级 管理人员列席会议。会议的召集、召开符合《中华人民共和国公司法》和《上海 凯利泰医疗科技股份有限公司章程》的规定。 二、董事会会议审议情况 1、审议未通过《关于选举王冲担任公司第六届董事会董事长的议案》 公司第六届董事会成员已由 2025 年第一次临时股东大会选举产生，代表 1/10 以上表决权的股东涌金投资控股有限公司、上海凯诚君泰投资有限公司提议 召开董事会临时会议，并提出提案《关于选举王冲担任公司第六届董事会董事长 的议案》。 依据《中华人民共和国公司法》《上海凯利泰医疗科技股份有 ...

重要提示内容 证券代码：300326 证券简称：凯利泰 公告编号：2025-016 上海凯利泰医疗科技股份有限公司 关于公司将被实施其他风险警示的提示性公告 本公司及董事会全体成员保证公告内容的真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 上海凯利泰医疗科技股份有限公司(以下简称"公司")在与众华会计师事务 所(特殊普通合伙)(以下简称"众华")沟通年报审计工作，众华将对凯利泰2024 年度的财务报表出具保留意见的审计报告、对凯利泰2024年12月31日的内部控制 出具无法表示意见的审计报告。 根据《深圳证券交易所创业板股票上市规则》第9.4条第（四）项规定，公 司股票交易在2024年年度报告披露后将被实施其他风险警示，请广大投资者注意 投资风险。 一、风险警示的情况说明 根据公司目前与众华的最新沟通情况，基于取得的审计证据及审计结果，众 华将对凯利泰2024年度的财务报表出具保留意见的审计报告、对凯利泰2024年12 月31日的内部控制出具无法表示意见的审计报告。根据《深圳证券交易所创业板 股票上市规则》第9.4条第（四）项规定"上市公司出现下列情形之一的，本所 对其股票交易实施其他风险警示：最 ...